tradingkey.logo

Nanovibronix Inc

NAOV
4.650USD
-0.150-3.13%
Close 11/07, 16:00ETQuotes delayed by 15 min
366.12KMarket Cap
LossP/E TTM

Nanovibronix Inc

4.650
-0.150-3.13%

More Details of Nanovibronix Inc Company

NanoVibronix, Inc. is a medical device company. The Company develops medical devices utilizing its patented low intensity surface acoustic wave technology. Its products include UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use. UroShield Ultra is similar to UroShield, but is designed to prevent bacterial colonization and biofilm formation in urinary catheters. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD, PainShield Plus and WoundShield. WoundShield is a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.

Nanovibronix Inc Info

Ticker SymbolNAOV
Company nameNanovibronix Inc
IPO dateApr 24, 2015
CEODr. Doron Besser, M.D.
Number of employees15
Security typeOrdinary Share
Fiscal year-endApr 24
Address969 Pruitt Piace
CityTYLER
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code75703
Phone19142333004
Websitehttps://nanovibronix.com/
Ticker SymbolNAOV
IPO dateApr 24, 2015
CEODr. Doron Besser, M.D.

Company Executives of Nanovibronix Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
2.00
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
2.00
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
462.00K
93.52%
New Zealand
20.00K
4.05%
Europe
8.00K
1.62%
Other
4.00K
0.81%
By Business
By Region
No Data

Shareholding Stats

Updated: Thu, Oct 2
Updated: Thu, Oct 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alpha Capital Aktiengesellschaft
0.95%
Armistice Capital LLC
0.46%
UBS Financial Services, Inc.
0.16%
Citi Investment Research (US)
0.03%
Tower Research Capital LLC
0.03%
Other
98.38%
Shareholders
Shareholders
Proportion
Alpha Capital Aktiengesellschaft
0.95%
Armistice Capital LLC
0.46%
UBS Financial Services, Inc.
0.16%
Citi Investment Research (US)
0.03%
Tower Research Capital LLC
0.03%
Other
98.38%
Shareholder Types
Shareholders
Proportion
Holding Company
0.95%
Hedge Fund
0.48%
Investment Advisor
0.16%
Research Firm
0.04%
Other
98.37%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
17
5.95K
0.68%
+2.34K
2025Q2
26
142.96K
5.53%
+80.02K
2025Q1
26
100.49K
7.64%
+70.73K
2024Q4
29
390.46K
7.75%
-206.57K
2024Q3
31
421.26K
15.22%
+83.76K
2024Q2
31
243.60K
8.84%
-214.51K
2024Q1
34
373.91K
18.23%
+170.33K
2023Q4
38
117.62K
5.71%
-262.96K
2023Q3
41
131.29K
7.90%
-1.54K
2023Q2
41
49.26K
2.96%
-111.70K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Alpha Capital Aktiengesellschaft
8.25K
0.95%
+4.93K
+148.55%
May 16, 2025
Armistice Capital LLC
3.99K
0.46%
+3.99K
--
Mar 31, 2025
UBS Financial Services, Inc.
1.37K
0.16%
+854.00
+165.50%
Jun 30, 2025
Citi Investment Research (US)
250.00
0.03%
+250.00
--
Jun 30, 2025
Tower Research Capital LLC
226.00
0.03%
+124.00
+121.57%
Jun 30, 2025
Morgan Stanley & Co. LLC
103.00
0.01%
-1.26K
-92.44%
Jun 30, 2025
Fashek (Christopher M)
34.00
0%
--
--
May 16, 2025
SBI Securities Co., Ltd.
--
0%
--
--
Jun 30, 2025
Brown (Stephen Russell)
2.00
0%
--
--
May 16, 2025
BofA Global Research (US)
1.00
0%
--
--
Jun 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Date
Type
Ratio
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
KeyAI